Tags

Type your tag names separated by a space and hit enter

Screening and Testing Pregnant Patients for SARS-CoV-2: First-Wave Experience of a Designated COVID-19 Hospitalization Centre in Montréal.
J Obstet Gynaecol Can. 2021 05; 43(5):571-575.JO

Abstract

OBJECTIVE

Coronavirus disease 2019 (COVID-19) may present asymptomatically in a large proportion of cases in endemic areas. Accordingly, universal testing has been suggested as a potential strategy for reducing transmission in the obstetrical setting. We describe the clinical characteristics of patients who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy at a designated COVID-19 hospitalization centre in Montréal, Québec.

METHODS

A single-centre retrospective cohort was constructed to include all pregnant patients who tested positive for SARS-CoV-2 between March 22 and July 31, 2020, and received care at the Jewish General Hospital. Initially, testing was restricted to at-risk patients, identified through the use of a screening questionnaire. Beginning on May 15, 2020, universal testing was implemented, and all pregnant patients admitted to the hospital were tested. Data were collected through chart review.

RESULTS

Of 803 patients tested for SARS-CoV-2 during the study period, 41 (5%) tested positive. Among those patients who were symptomatic, the most commonly reported symptoms were cough (53%), fever (37%), dyspnea (30%), and anosmia and/or ageusia (20%). Before the implementation of universal testing, 13% (3 of 24) of patients with SARS-CoV-2 were asymptomatic. After implementation of universal testing, 80% (8 of 10) of patients with SARS-CoV-2 were asymptomatic.

CONCLUSION

Our findings suggest that most pregnant patients with SARS-CoV-2 are asymptomatic or have mild symptoms of COVID-19. Particularly in endemic areas, universal testing of pregnant patients presenting to the hospital should be strongly considered as an important measure to prevent in-hospital and community transmission of COVID-19.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, McGill University, Montréal, QC.Department of Obstetrics and Gynecology, McGill University, Montréal, QC.Department of Medicine, Division of General Internal Medicine, McGill University Health Centre, Montréal, QC.Department of Obstetrics and Gynecology, McGill University, Montréal, QC; Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Jewish General Hospital, Montréal, QC. Electronic address: haim.abenhaim@gmail.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33358711

Citation

Trahan, Marie-Julie, et al. "Screening and Testing Pregnant Patients for SARS-CoV-2: First-Wave Experience of a Designated COVID-19 Hospitalization Centre in Montréal." Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'obstetrique Et Gynecologie Du Canada : JOGC, vol. 43, no. 5, 2021, pp. 571-575.
Trahan MJ, Mitric C, Malhamé I, et al. Screening and Testing Pregnant Patients for SARS-CoV-2: First-Wave Experience of a Designated COVID-19 Hospitalization Centre in Montréal. J Obstet Gynaecol Can. 2021;43(5):571-575.
Trahan, M. J., Mitric, C., Malhamé, I., & Abenhaim, H. A. (2021). Screening and Testing Pregnant Patients for SARS-CoV-2: First-Wave Experience of a Designated COVID-19 Hospitalization Centre in Montréal. Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'obstetrique Et Gynecologie Du Canada : JOGC, 43(5), 571-575. https://doi.org/10.1016/j.jogc.2020.11.001
Trahan MJ, et al. Screening and Testing Pregnant Patients for SARS-CoV-2: First-Wave Experience of a Designated COVID-19 Hospitalization Centre in Montréal. J Obstet Gynaecol Can. 2021;43(5):571-575. PubMed PMID: 33358711.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Screening and Testing Pregnant Patients for SARS-CoV-2: First-Wave Experience of a Designated COVID-19 Hospitalization Centre in Montréal. AU - Trahan,Marie-Julie, AU - Mitric,Cristina, AU - Malhamé,Isabelle, AU - Abenhaim,Haim A, Y1 - 2020/11/05/ PY - 2020/09/01/received PY - 2020/11/02/revised PY - 2020/11/02/accepted PY - 2020/12/29/pubmed PY - 2021/6/23/medline PY - 2020/12/28/entrez KW - COVID-19 testing KW - SARS-CoV-2 SP - 571 EP - 575 JF - Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC JO - J Obstet Gynaecol Can VL - 43 IS - 5 N2 - OBJECTIVE: Coronavirus disease 2019 (COVID-19) may present asymptomatically in a large proportion of cases in endemic areas. Accordingly, universal testing has been suggested as a potential strategy for reducing transmission in the obstetrical setting. We describe the clinical characteristics of patients who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy at a designated COVID-19 hospitalization centre in Montréal, Québec. METHODS: A single-centre retrospective cohort was constructed to include all pregnant patients who tested positive for SARS-CoV-2 between March 22 and July 31, 2020, and received care at the Jewish General Hospital. Initially, testing was restricted to at-risk patients, identified through the use of a screening questionnaire. Beginning on May 15, 2020, universal testing was implemented, and all pregnant patients admitted to the hospital were tested. Data were collected through chart review. RESULTS: Of 803 patients tested for SARS-CoV-2 during the study period, 41 (5%) tested positive. Among those patients who were symptomatic, the most commonly reported symptoms were cough (53%), fever (37%), dyspnea (30%), and anosmia and/or ageusia (20%). Before the implementation of universal testing, 13% (3 of 24) of patients with SARS-CoV-2 were asymptomatic. After implementation of universal testing, 80% (8 of 10) of patients with SARS-CoV-2 were asymptomatic. CONCLUSION: Our findings suggest that most pregnant patients with SARS-CoV-2 are asymptomatic or have mild symptoms of COVID-19. Particularly in endemic areas, universal testing of pregnant patients presenting to the hospital should be strongly considered as an important measure to prevent in-hospital and community transmission of COVID-19. SN - 1701-2163 UR - https://www.unboundmedicine.com/medline/citation/33358711/Screening_and_Testing_Pregnant_Patients_for_SARS_CoV_2:_First_Wave_Experience_of_a_Designated_COVID_19_Hospitalization_Centre_in_Montréal_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1701-2163(20)30880-X DB - PRIME DP - Unbound Medicine ER -